PBAX stockholders approve extension of business combination deadline to April 2023

CERO THERAPEUTICS HOLDINGS, INC.

Stockholders voted 20,111,798 for and 251,977 against the charter amendment extending the deadline.
Charter amended to extend business combination period from Jan 8, 2023 to Apr 8, 2023, with up to three one-month extensions to July 8, 2023.
Sponsor provided up to $1.5M promissory note; $325,000 deposited into trust for the first extension to Apr 8, 2023.
Note is non-interest bearing, convertible into units at $10/unit upon a business combination, and repayable only from non-trust funds if no deal by July 8, 2023.
Trust agreement amended to reflect the new deadlines and extension deposit requirements.

item 1.01 item 5.07 item 2.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC.: Amended charter to extend business combination period from January 8, 2023 to April 8, 2023 and allow board to further extend up to three additional one-month periods (effective 2022-12-20).

Change: charter amendment
Effective: 2022-12-20

Exact text from the filing

On December 16, 2022, the Company’s stockholders approved an amendment (the “ Charter Amendment ”) to the Company’s amended and restated certificate of incorporation (the “ Charter ”) to extend the business combination period for an additional three months, from January 8, 2023 to April 8, 2023, and provide its board of directors the ability to further extend the date by which the Company has to consummate a business combination up to three additional times for one month each time, for a maximum of six additional months. On December 20, 2022, the Company filed the Charter Amendment with the Secretary of State of the State of Delaware.

View on SEC.gov

84 governance changes filed in the last 30 days. Browse all governance changes →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-309120

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.